Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06508762 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993

A Phase 1 study of Pain, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT06508762 is a Phase 1 study of Pain that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 24 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06508762, a Phase 1 study of Pain, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-993 in healthy adult participants.

Conditions Studied

Interventions

  • DRUG VX-993

Study Locations (1)

Utah

  • ICON Salt Lake City - Salt Lake City

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2024-07-26
Est. Completion 2024-09-10
Phase Phase 1

Sponsor

Vertex Pharmaceuticals Incorporated

191 total trials

What the Registry Record Tells You About NCT06508762

The ClinicalTrials.gov registry entry for NCT06508762 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (92% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which VX-993 is the first listed.

NCT06508762 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT06508762 about?

NCT06508762 is a clinical study titled "A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993". The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-993 in healthy adult participants.

What is the current status of trial NCT06508762?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-07-26. Estimated completion is 2024-09-10.

What conditions does trial NCT06508762 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT06508762?

The interventions under investigation include: VX-993 (DRUG).

Who is sponsoring clinical trial NCT06508762?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06508762 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.